Bladder Cancer Prognosis Modified By Genetic Variants

Share this content:
Bladder Cancer Prognosis Modified By Genetic Variants
Bladder Cancer Prognosis Modified By Genetic Variants

(HealthDay News) — Certain genetic variants may modify bladder cancer prognosis, according to a study published online March 26 in BJU International.

Angeline S. Andrew, PhD, from the Geisel School of Medicine in Lebanon, NH, and colleagues examined genetic variants hypothesized to modify bladder cancer prognosis in a cohort of 563 patients with urothelial-cell carcinoma.

Participants were followed after diagnosis to ascertain recurrence and survival status, and the correlations between single nucleotide polymorphisms (SNPs) and prognosis end points were assessed.

RELATED: Urologic Cancers Resource Center

The researchers identified shorter time to first recurrence for patients with aldehyde dehydrogenase 2 variants (adjusted non-invasive hazard ratio, 1.90).

Patients with non-invasive tumors heterozygous for DNA repair X-ray cross-complementing protein 4 genotype had longer survival than those with wild-type genotype (adjusted hazard ratio, 0.53).

Patients with a variant allele in vascular cellular adhesion molecule 1 who were treated with immunotherapy had shorter time to recurrence (P interaction < 0.001).

"Our analysis suggests candidate prognostic SNPs that could guide personalized bladder cancer surveillance and treatment," the researchers wrote.

References

  1. Andrew AS, Gui J, Hu T, et al. Genetic polymorphisms modify bladder cancer recurrence and survival in a USA population-based prognostic study. BJU Int. 2014;doi:10.1111/bju.12641.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs